# EDGAR Filing Document

**Accession Number:** 0001919246
**File Stem:** 0001753926-25-001606
**Filing Date:** 2025-10
**Character Count:** 27586
**Document Hash:** 97746917148d8b20864d840a1a5a1e4e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001753926-25-001606.hdr.sgml**: 20251014

**ACCESSION NUMBER**: 0001753926-25-001606

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 34

**CONFORMED PERIOD OF REPORT**: 20251014

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20251014

**DATE AS OF CHANGE**: 20251014

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Pelthos Therapeutics Inc.
- **CENTRAL INDEX KEY:** 0001919246
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 863335449
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41964
- **FILM NUMBER:** 251389684

**BUSINESS ADDRESS:**
- **STREET 1:** 4020 STIRRUP CREEK DRIVE
- **STREET 2:** SUITE 110
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703
- **BUSINESS PHONE:** 919-908-2422

**MAIL ADDRESS:**
- **STREET 1:** 4020 STIRRUP CREEK DRIVE
- **STREET 2:** SUITE 110
- **CITY:** DURHAM
- **STATE:** NC
- **ZIP:** 27703

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Channel Therapeutics Corp
- **DATE OF NAME CHANGE:** 20241118

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Chromocell Therapeutics Corp
- **DATE OF NAME CHANGE:** 20220323

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **October 14, 2025**

**Pelthos Therapeutics Inc.**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-41964** | **86-3335449** |
| (State or other jurisdiction<br>of incorporation) | (Commission File Number) | (IRS Employer<br>Identification No.) |

---

---

| | |
|:---|:---|
| **4020 Stirrup Creek Drive, Suite 110**<br> **Durham, NC** | **27703** |
| (Address of registrant's principal executive office) | (Zip code) |

---

Registrant's telephone number, including area code: **(919) 908-2400**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, par value $0.0001 per share | PTHS | The NYSE American LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

On October 14, 2025, Pelthos Therapeutics Inc. (the "Company") made available a presentation on its website. A copy of the presentation is attached hereto as Exhibit 99.1. Information contained on the Company's website is not incorporated by reference into and should not be considered to be part of this Current Report on Form 8-K.

The information contained in this Item 7.01, including Exhibit 99.1 attached hereto, which is incorporated into this Item 7.01 by reference, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly set forth by specific reference in such filing. The information set forth in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed an admission as to the materiality of any information in this Current Report on Form 8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.

**Forward-Looking Statements**

Exhibit 99.1 attached hereto contains, and may indicate, forward-looking statements within the meaning of Section 27A of the Securities Act, Section 21E of the Exchange Act and as defined in the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements that express the Company's intentions, beliefs, expectations, strategies, predictions or any other statements related to the Company's future activities, or future events or conditions, including without limitation, those statements relating to the success of the launch for Zesluvmi, timing, progress and results of any preclinical and clinical trials, its estimates regarding the potential market opportunity for Zelsuvmi, its ability to develop its pipeline, its ability to protect its intellectual property and enforce its intellectual property rights, and its ability to execute its development strategy and sustain its competitive position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the Company's limited operating history, the Company's ability to establish its market development capabilities to commercialize its products and generate any revenue, and the Company's ability to maintain regulatory approval of Zelsuvmi, which can be identified by terminology such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict, "project," "seek," "should," "target," "will," "would" and other similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are not historical facts and are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by its management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict, many of which are beyond the Company's control. Any forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date of this Form 8-K, except as required by applicable law.

**EXHIBIT INDEX**

---

| | |
|:---|:---|
| **<u>Exhibit Number</u>** | **<u>Description of Documen</u>t** |
| [99.1](g084975_ex99-1.htm) | [Company Presentation](g084975_ex99-1.htm) |

---

<u>**SIGNATURES**</u>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  | **Pelthos Therapeutics Inc.** | **Pelthos Therapeutics Inc.** | **Pelthos Therapeutics Inc.** |
| Date: October 14, 2025 | By: | /s/ Francis Knuettel II | /s/ Francis Knuettel II |
|  |  | Name:  | Francis Knuettel II |
|  |  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](img001.jpg)

Corporate Presentation Q 4 2 02 5 1

![](img002.jpg)

Legal Disclaimer This presentation of Pelthos Therapeutics Inc. ("we", "us", "our" or the "Company") contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict, "project," "seek," "should," "target," "will," "would" or similar expressions and the negatives of those term are intended to identify forward-looking statements. Forward-looking statements reflect management's current expectations, are based on judgments and assumptions, are inherently uncertain and are subject to risks, uncertainties and other factors, which could cause the Company's actual results, performance or achievements to differ materially from expected future results, performance or achievements expressed or implied in those forward-looking statements. Examples of these forward-looking statements and the related risks, uncertainties and other factors include, but are not limited to, the following: the success of the launch for Zesluvmi, timing, progress and results of any preclinical and clinical trials, its estimates regarding the potential market opportunity for Zelsuvmi, its ability to develop its pipeline, its ability to protect its intellectual property and enforce its intellectual property rights, and its ability to execute its development strategy and sustain its competitive position. Actual future results and trends may differ materially depending on a variety of factors, including, but not limited to, the Company's limited operating history, the Company's ability to establish its market development capabilities to commercialize its products and generate any revenue, and the Company's ability to maintain regulatory approval of Zelsuvmi. Forward-looking statements are provided to allow potential investors the opportunity to understand management's beliefs and opinions in respect of the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them. Any forward-looking statement in this presentation, in any related presentation supplement and in any related free writing presentation reflects our current view with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our business, results of operations, industry and future growth. You should read this presentation with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future. 2

![](img003.jpg)

Corporate Profile Pelthos Therapeutics is a bio-pharmaceutical company committed to commercializing innovative, safe, and efficacious therapeutic products to help patients with unmet treatment burdens • • • • • Commercial launch of first drug Zelsuvmi, for the treatment of Molluscum contagiosum ("MC") in July 2025 First and only at home treatment for a large, underserved market treating contagious viral disease ❖ 16.7 million affected people ❖ Up to 6 million annual cases in the U.S. ❖ Total addressable market worth in excess of $20 billion at our WAC Experienced management team with over 20 successful prior drug launches and continued growth, including Cosentyx, Otezla, Ohtuvayre, Xifaxan Upside option on NaV pain programs from predecessor Current peak Net Revenue forecast of $175M per annum by 2028 and currently meeting or exceeding internal milestones Key Data Points (as of 10/10/25, except where noted) Ticker PTHS Stock Price $23.26 O/S Shares of Common Stock (on an as converted basis)\* 8.8M Market CAP ~$205M Avg. Daily Trading Volume 31,100 shares (NYSE) Cash at close of merger $27.5M Investment to date >$400M 3

![](img004.jpg)

Management Team Scott Plesha \| Chief Executive Officer • >30 years of experience in the pharmaceutical industry, including two decades building and leading specialty pharma commercial efforts • President and Chief Commercial Officer at BDSI until it was acquired by Collegium Pharmaceutical in 2022 • Grew BDSI sales from $5 million to $160 million • Previously served as Senior Vice President of Gastrointestinal Sales at Salix Pharmaceuticals. During fifteen-year tenure at Salix, led nationwide salesforce that grew product sales to more than $1.5 billion annually • Earned a BA in Pre-Medicine and Pre-Medical Studies at DePauw University and pursued graduate studies in Dentistry at Indiana University Dental School Frank Knuettel \| Chief Financial Officer • 30 years of management experience in growing early-stage companies • Raised more than $400 million via venture, public equity and debt offerings and managed more than 15 mergers and acquisition transactions along with large-scale licensing transactions with fortune 50 companies • Holds numerous board positions, at both public and private companies, including Etheros Pharmaceuticals • Earned an MBA from The Wharton School and a BA from Tufts University Sai Rangarao \| Chief Commercial Officer • • • • • • >18 years of experience leading, launching, and marketing pharmaceutical products VP of Marketing & Head of Neurology Sales at Collegium Pharmaceutical VP of Marketing & Commercial Operations at BDSI, until it was acquired by Collegium in 2022 Head of US Dermatology Marketing for Otezla at Celgene leading to acquisition by Amgen for $13 Billion Member of the commercial and marketing organization at Novartis Pharmaceuticals that launched COSENTYX® in the U.S Earned an MS in Bioscience Regulatory Affairs from The Johns Hopkins University, an MBA and MS from the New Jersey Institute of Technology, and a BS in Computer Science from Indiana University of Pennsylvania 4

![](img005.jpg)

Board of Directors Richard Baxter Peter Greenleaf, Chairman Todd Davis Ezra Friedberg Matt Pauls Richard Malamut , MD Scott Plesha 5

![](img006.jpg)

Molluscum & Zelsuvmi Overview

![](img007.jpg)

Molluscum Contagiosum A highly infectious viral condition primarily affecting children 1 year of age or older Point prevalence of 3-6 million children (ages 0-16) in the U.S. Molluscum Contagiosum is caused by a pox virus and is characterized by small, round, firm, umbilicated, often painless bumps. Even after healing, reinfection is possible if in contact with an infected person or object4. ~17 million people infected in the U.S. There are four known types of MC virus (MCV1, 2, 3, 4) with MCV1 being the most common1 MC can take up to five years to resolve without treatment2 Peak incidence between 1-10 years of age. Up to 73% of children go untreated3 Untreated Molluscum Contagiosum Has Severe Effects Infection, Persistence, and Spread Autoinoculation2 Highly contagious to others Pain & Skin Irritation ↑ risk of secondary bacterial infections2 Potential worsening of atopic dermatitis Itching, redness Visible and Psychological Impacts Inflammation Anxiety Social withdrawal 1) Hebert AA, Bhatia N, Del Rosso JQ. Mollu scu m Contagiosu m: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 20 23 Au g;16(8 Su ppl 2):S4-S11. PMID: 3 7636018; PMCID: PMC10453 394. 2.)Ludmann P. American Academy of Dermatology. Mollu sc um c on tagiosu m. 4 Oc tober 2023 . 3) Basdag H, Rainer BM, Cohen BA. Mollusc um c ontagiosu m: to treat or not to treat? Experience with 170 children in an outpatient c linic setting in the northeastern United States. Pediatr Dermatol. 20 15;32(3):353-35 7. doi:10.1111/pde.125 04. 4) Sch affer JV, Berger E M. Mollusc um Contagiosum. JAMA Dermatol. 20 16;152(9):1072. doi:10.1001/jamadermatol.2016.2367. 5) CDC. Clinical Overview of Mollusc um Contagiosum. Jan 2025 7

![](img008.jpg)

Zelsuvmi Has the Potential to Shift MC Treatment Paradigm Current Options Zelsuvmi • Other available topical treatment requires in-office visits every 3 weeks2 • Painful, destructive treatments3 • Necessitates travel to HCP offices, adding to the time burden for MC patients and caregivers2 • Remaining treatment options such as off-label drugs / natural remedies have unproven efficacy4 • Daily application that can be started immediately Breakthrough Product, Breakthrough Results 58.1% Mean MC Lesion reduction count(1) • Attractive safety profile demonstrated in clinical trials with no / minimal scarring5,6 • First FDA approved medication for molluscum that can be applied at home by patients or caregivers5 • Demonstrated, proven efficacy across key primary and secondary endpoints in clinical trials6 1.)Least-squares mean coun t reduction. See Figure 9: Brow nin g JC, Hebert A, Enloe C, Cartwrigh t M, Maeda-Chub ac hi T. Berdazimer Gel 10.3 % is a Clinically Meaningful Therapeutic Intervention for Mollu sc um Contagiosu m. Abstract and poster presented at Fall Clinical 2024. Las Vegas, NV. October 24 -27, 2024. 2.) Eichenf ield LF, Kwong P, Gonzalez ME, et al. Safety and E ffic ac y of VP-10 2 (Cantharidin, 0 .7% w/ v) in Molluscu m Contagiosu m by Body Region: Post hoc Pooled Analyses from Two Phase III Ran domized Trials. J Clin Aesthet Dermatol. 20 21;14(10):42-47. 3.) Hebert AA, Bhatia N, Del Rosso JQ. Molluscum Contagiosum: Epidemiology, Considerations, Treatment Options, and Therapeutic Gaps. J Clin Aesthet Dermatol. 20 23;16(8 Su ppl 1):S4-S11. 4 .) Ong SK, Hoft I, Siegfried E . Analysis of over-the-cou nter products marketed to treat molluscum con tagiosum. Pediatr Dermatol. 20 21;3 8(5):140 0-14 03. doi:10.1111/pde.14776. 5 .) Zelsuvmi Package Insert. 6.) Su garman JL, Hebert A, Browning JC, et al. Berdazimer gel for mollusc um c ontagiosu m: An integrated an alysis of 3 randomized controlled trials. J Am Acad Dermatol. 20 24;90(2):299-30 8. doi:10.1016/j.jaad.2023.0 9.066Ong 8

![](img009.jpg)

Zelsuvmi Efficacy Shown in Phase 3 Clinical Trials Drives Commercial Launch Population Intervention Key Study Highlights 808 Males, 790 Females 1,598 participants randomized Patients who applied Zelsuvmi for 12 weeks achieved a mean and median reduction in lesion count of 58% and 82%, respectively, compared to 36% and 43% for patients who applied a vehicle control gel Mean Lesion Count Reduction(1) Immunocompetent children and adults aged ≥6 months with 3-70 raised MC lesions Mean age: 6.7 years (Range: 0.9 – 76.6 years) B-SIMPLE4 Study Locations 55 Clinics across the US 82.4% 58.1% 917 - Zelsuvmi Topical, once-daily application of Zelsuvmi (berdazimer gel, 10.3%) to all active MC lesions for up to 12 weeks 681 - Vehicle Topical, once-daily application of vehicle control gel to all active MC lesions for up to 12 weeks Median Lesion Count Reduction(1) 35.7% Zelsuvmi Control 42.6% Zelsuvmi Control Safety B-SIMPLE4 Primary Outcome • Application site reactions were the most common adverse reaction associated with Zelsuvmi • Common application site reactions included mild pain and mild erythema (caused by increased blood flow) • Minimal scarring incidences witnessed 32.4% of patients treated with Zelsuvmi achieved complete clearance of MC lesions at week 12, compared to 19.7% of patients treated with vehicle control gel in the BSIMPLE-4 pivotal Phase 3 trial 1) p-value <0.000 1, f avoring Zelsuvmi .. Source: Sugarman JL, Hebert A, Brow nin g JC, Paller AS, Stripling S, Green LJ, Cartwrigh t M, Enloe C, W ells N, Maeda-Chubac hi T. Berd azimer gel for molluscum contagiosum: An integrated analysis of 3 randomized controlled trials. J Am Acad Dermatol. 20 23 Oct 5:S0190-9622(23)02890-6. doi: 10.10 16/j.jaad.20 23.09.066.Epub ahead of print. PMID: 37804936. 9

![](img010.jpg)

Phase 3 Trial Results Zelsuvmi showed statistically significant benefit vs. vehicle after 2 weeks of therapy and through out the entire 12-week length of the Phase 3 studies Least Squares Mean Lesion Reduction(1) Baseline Week 2 0.0% Week 4 Week 8 Week 12 Baseline Week 2 0.0% -1.1 % -10.7% Median Lesion Reduction(2) Week 8 Week 12 0.0% -9.5% -9.0% Week 4 -10.0% -28.6% -21 .6% -27.8% - 25 .1% -42.6% -35.7% -59.4% -43.5% Zelsuvmi (n= 917) Vehicle (n= 681) - 58 .1% Zelsuvmi (n= 917) Vehicle (n= 681) -82.4% P<0.0001 at all time points, favoring ZelsuvmiTM 1) Figure 9: Browning JC, Hebert A, Enloe C, Cartwright M, Maeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Mean in gful Therapeutic Intervention for Molluscum Contagiosu m. Abstract and poster presentedatFall Clinical 2024. Las Vegas, NV. October 24-27, 2024. 2) Figure 10: Browning JC, Hebert A, Enloe C, Cartwright M, M aeda-Chubachi T. Berdazimer Gel 10.3% is a Clinically Meaningful Therapeu ticIntervention f or Mollu scum Contagiosum. Abstract and poster presen ted at Fall Clin ic al 20 24. Las Vegas, NV. Octobe r 24-27, 2024. CONFIDENTIAL 10

![](img011.jpg)

Zelsuvmi Commercial Overview

![](img012.jpg)

Activating Key Leverage Points Is Essential to Maximize the Commercial Potential of Zelsuvmi Key Leverage Points 01 Up to 6 million new cases each year with an average untreated resolution time of 13 months, during which disease is highly contagious 02 Treated patients respond well to Zelsuvmi and experience dramatic reduction in lesion count and mean time to resolution Refills 03 FDA approved for 12-week treatment regimen, but internal forecasts assume lower Price and Revenue 04 WAC of $1,950 per unit. Disclosed peak net revenues of $175M per annum by 2028 Addressable Patient Population Treated Patients / Initial Prescriptions 12

![](img013.jpg)

Commercial Launch Overview Sales Force of 50 Territory Managers Reaching Highest Molluscum Treaters Fully built out commercial team: Territory managers supported by Sales Training, Marketing, Commercial Operations & Market Access teams 13

![](img014.jpg)

Zelsuvmi Tactical Launch Approach Driving Awareness and Adoption Health Care Providers Education KOL Education Live & Virtual Educational Speaker Development National & Regional Conference Presence Now Available Congress Booth & Virtual Booth CRM Platform: Education & Communication MD ZELSUVMI Experience Videos Consumer/Patient Education & Awareness How to Start & Use Infographic Brochure Advocacy & Partnerships ZELSUVMI GO Patient Support Program Banner Ads, Native & Paid Search Patient CRM Platform Telehealth Now Available Website with Patient-Specific Education Social Media Patient Testimonial Videos 14

![](img015.jpg)

Strong Uptake of Zelsuvmi in Early Launch Phase Zelsuvmi TRx Units Zelsuvmi Prescriber Count 1,800 900 1,546 1,600 1,400 700 1,200 600 935 1,000 530 500 800 400 600 300 400 797 800 200 235 200 146 100 0 0 Jul-25 Aug-25 Sep-25 Total of 2,716 Prescribed Units During Q3 2025 Data Source: Symphony Health- Metys Data Jul-25 Aug-25 Sep-25 Total of 1,169 Unique Prescribers During Q3 2025 15

![](img016.jpg)

NitricilTM Platform & NaV1.7 Pipeline Overview

![](img017.jpg)

The NitricilTM Platform Macromolecular platform to achieve stable, tunable and druggable delivery of nitric oxide Tunable Stable Druggable Real-Time Nitric Oxide Release Initial Burst Extended Tail New Chemical Entity (NCE) Proprietary platform enabling development of NCEs with sustained delivery of nitric oxide Proprietary formulations, targeted to each indication, enable tunable dosing Multiple drug candidates with unique nitric oxide delivery and proven target engagement 17

![](img018.jpg)

Nitricil Platform Pipeline Asset Description Asset Description Approx Time to NDA Filing Market Potential SB204 (Acne) Berdazimer topical gel, 3.4% for treatment of acne vulgaris. Phase 3 Clinical stage. 4.5 years $$$ SB414 (AD/Psoriasis) Berdazimer topical cream, dose TBD, for treatment of mild to moderate atopic dermatitis. Phase 1/2 Clinical stage. 7.5 years $$$(AD) $$(Psoriasis) SB208 (Tinea Pedis -> Onychomycosis) Low alcohol berdazimer topical gel for treatment of athlete's foot with label expansion for onychomycosis following initial approval. Phase 2/3 Clinical stage. 5 years (T. Pedis) 6.5 years (Onychomycosis) $$$$$ SB208 (Tinea Pedis + Onychomycosis) Low alcohol berdazimer topical gel for treatment of both athlete's foot and onychomycosis. Phase 2/3 Clinical stage. 6.5 years $$$$$ SB207 (EGW/PAW) Berdazimer topical gel, 10.3% for treatment of external genital and perianal warts. Same active gel (Tube A) as Zelsuvmi but different hydrogel (Tube B) formulation. Phase 3 clinical stage. 6.5 years $18

![](img019.jpg)

NaV1.7 Pipeline Product/ Indication Asset Description Approximate Time to NDA Filing Market Potential CT2000 Eye Drops Chronic Ocular Pain CC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready 3-4 years $8 billion globally CT2000 Eye Drops Acute Ocular Pain CC8464 1%, 1.25% and 1.5% ophthalmic solution Phase 1-2a ready 2-3 years $400 million globally CT3000 depot Nerve Blocks CC8464 5% and 10% depot injectable Preclinical Stage 5+ years $300-570 million globally CC8464 Oral Erythromelalgia CC8464 melt-granulation capsules 50mg, 100mg, 400mg Phase 1 stage 5+ years $2.4 billion globally CC8464 Oral Small Fibre Neuropathy CC8464 melt-granulation capsules 50mg, 100mg, 400mg Preclinical stage 5+ years $50 million – 100 million CC8464 Oral Acute Pain CC8464 melt-granulation capsules 50mg, 100mg, 400mg Preclinical stage 5+ years $20 billion globally 19

![](img020.jpg)

Key Highlights Commercially Launched Zelsuvmi was FDA approved In January 2024, and commercially launched in July 2025 as the first and only at-home treatment aimed to revolutionize how MC is treated today for patients ≥ 1 year old Significant Unmet Need and Sizeable Market Opportunity Large market potential, with up to 6M new cases annually. Treatment of new cases alone has a total addressable market potential of over $20 billion Zelsuvmi Differentiated Characteristics Strong, Proven Clinical Efficacy CONFIDENTIAL Zelsuvmi is a topical gel that uses proprietary nitric oxide release technology and is applied once daily at-home with very good safety profile; opportunity to replace and complement current approved treatment options that are painful and require in-person visits In the combined results from the three Phase 3 clinical trials, patients who applied Zelsuvmi weeks achieved a mean and median reduction in lesion count of 58% and 82%, respectively, compared to 36% and 43% for patients who applied a vehicle control gel for 12 Barriers to Entry Pelthos' bespoke manufacturing processes require a dedicated line and manufacturing of API under extremely high pressures with stringent safety protocols and procedures; robust set of FDA Orange Book listed patents Biopharmaceutical Platform Poised for Growth Pelthos is strategically positioned to execute and integrate complex, synergistic acquisitions, serving as a platform for investors seeking a strong foothold in the specialty biopharmaceutical market Financial Opportunity Retained Channel Therapeutics' pipeline of several NaV1.7 programs following business combination, providing further upside optionality. Currently exploring best monetization strategies. 20

![](img021.jpg)

Thank You Contacts Investor Inquiries: Mi ke M oyer L ife Sci A dvi sors, L LC Ma n agi ng Dire ct or mmoy er @l ife s cia d vi sor s .com Me dia : KW M Commu n ica ti ons Ke ll ie W al sh / Ra ch el Ke s s le r p e lth os @ kwmcommu n ica ti ons . com (914) 315-607 2 21